|
Dec 19
|
Checkpoint Therapeutics, Inc.'s (NASDAQ:CKPT) Profit Outlook
|
|
Dec 18
|
UPDATE 1-US FDA declines to approve Checkpoint Therapeutics' skin cancer therapy
|
|
Dec 18
|
U.S. Food and Drug Administration Issues Complete Response Letter for Cosibelimab Solely Due to Inspection Findings at Third-Party Manufacturer
|
|
Dec 5
|
Checkpoint Therapeutics Strengthens Intellectual Property Protection for Cosibelimab with New U.S. Patent Issuance
|
|
Jun 28
|
Checkpoint Therapeutics Announces Presentation of New Cosibelimab Pharmacokinetic Data Supporting Extended-Interval Dosing
|